MedPath

Punch Minigraft Versus Transverse Needling or Combination of Both in Treatment of Non-Segmental Vitiligo

Not Applicable
Conditions
Vitiligo
Interventions
Procedure: Transverse needling
Procedure: Punch minigrafts followed by transverse needling
Other: Oral pulse steroid with narrow band
Registration Number
NCT03872804
Lead Sponsor
Alexandria University
Brief Summary

This study is to evaluate the effectiveness and tolerability of autologous punch minigraft, transverse needling technique or combination of both followed by narrow band ultraviolet B phototherapy (311 nm) in the treatment of patients with stable non-segmental vitiligo lesions.

Detailed Description

Vitiligo is a common pigmentary cutaneous disorder occurring with an incidence of 1-2% worldwide, without predilection for sex or race.

The disease is characterized by gradual loss of the normal color of the skin resulting from melanin pigment loss due to the underlying destruction of the melanocyte.

Vitiligo is a multifactorial disorder with many theories explaining its pathogenesis such as autoimmunity, self-destructing mechanisms,neural mediators, biochemicals,an imbalance of epidermal cytokines and genetic factors.

Vitiligo is not a life-threatening disease,but it may cause a major social and emotional distress with significant impairment in the quality of life.

Clinically; vitiligo is classified into segmental, non-segmental and unclassified vitiligo .Non-segmental includes generalized, acrofacial,universal, mucosal (more than one mucosal site) , mixed (associated with segmental vitiligo) and other rare variants. Segmental vitiligo includes uni- ,bi- or pluri-segmental subtypes. Unclassified includes focal or mucosal (one site) subtypes.

Treatment options for vitiligo include attempting repigmentation of affected areas,

depigmentation of non-involving skin or camouflage if neither is effective.Repigmentation could be attempted using medical therapy, surgical modalities.

Topical medications include corticosteroids or calcineurin inhibitors.Ultraviolet radiation therapy, such as narrow-band ultraviolet B light (NB-UVB), is also widely used. It is minimally invasive, has few adverse effects and provides a good response rate. Excimer laser or light has become available for use recently, and favorable treatment results have been reported.

When medical treatments are ineffective, surgical treatment is indicated.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Adult patients (>16 years old) of either gender having stable non segmental vitiligo, that is resistant to other lines of repigmentation therapy.
  • Lack of progression of old lesions with the past 6 months.
  • No development of new lesions
  • Absence of history of koebner phenomenon.
  • Absence of confetti lesions or hypopigmented lesions within the past 6 months.
  • Presence of repigmentation of depigmented areas by medications or spontaneously in the past 6 months.
  • While resistance to therapy will be judged after receiving standard protocol of NB-UVB together with oral mini pulse dexamethasone at a dose of 2.5 mg on two consecutive weekly days for 3 months.
  • Patients having lesions showing absence or poor repigmentation after this regiment will be considered resistant to medical repigmentation and indicated to surgery.
Exclusion Criteria
  • Cases of active, progressive disease lacking criteria of stability previously mentioned.
  • Patients with segmental or universal vitiligo covering more than 70% body surface area.
  • Patients with known associated autoimmune diseases, bleeding tendency, current or history of skin neoplasia, photosensitive disorders or any contraindications to corticosteroids therapy.
  • Patients with tendency towards hypertrophic scars or keloid formation.
  • Pregnant female and lactating mothers.
  • Patients with emotional and psychological instability.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Vitiligo patientPunch minigrafts followed by transverse needlingPatient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
Vitiligo patientOral pulse steroid with narrow bandPatient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
Vitiligo patientTransverse needlingPatient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
Primary Outcome Measures
NameTimeMethod
Evaluation of Type, pattern and extent of repigmentation.6 months

Serial photography will be done to evaluate type, pattern and extent of repigmentation.

Assessment of repigmentation6 months

Assessments of repigmentation will be performed by two blinded dermatologists using a 5-point scale; grade 0 (no repigmentation), grade 1 (1%-5%), grade 2 (6%-25%), grade 3 (26%-50%), grade 4 (51%-75%) and grade 5 (76%-100%)

Digital assessment of the size of the lesion and of the depigmented versus repigmented area6 months

Digital assessment of the size of the lesion and of the depigmented versus repigmented area using Adobe photoshop software

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Omneya abd el aziz el zagh

🇪🇬

Alexandria, Egypt

© Copyright 2025. All Rights Reserved by MedPath